Next-Generation Biomanufacturing Market Size, Share & Trends Analysis Report By Medical Applications (Monoclonal Antibodies, Hormones, Vaccines, Recombinant Proteins, Other Applications), By Products, By Workflow, By End-User, By Region, And By Segment Forecasts, 2025-2034
Next-Generation Biomanufacturing Market Size is valued at 24.9 Billion in 2024 and is predicted to reach 80.0 Billion by the year 2034 at a 12.6% CAGR during the forecast period for 2025-2034.

Key Industry Insights & Findings from the Report:
- Supportive regulatory frameworks and guidelines from agencies like the FDA and EMA encourage the adoption of next-generation biomanufacturing technologies.
- The ability to adapt fastly to changing market demands and customize production processes for different biologics is a significant driving factor.
- Asia Pacific region dominated the market & accounted for a global revenue share in 2023.
Biomanufacturing is the production process of biomolecules by utilizing biological services to use in medical & industrial applications. Next-generation biomanufacturing products provide superior services in terms of quality and efficiency compared to first-generation biomanufacturing products.
Major driving factors of the next-generation biomanufacturing market are rising government funding for the development of modern bioprocessing technologies, rapid adoption of advanced technologies, increasing investments by pharma companies to develop & adopt next-generation biomanufacturing products, growing patient population, and increasing awareness among the people regarding the benefits of next-generation biomanufacturing. With the growing demand for drugs and therapies, many biopharmaceutical companies prefer adopting next-generation biomanufacturing services to balance the process design, performance, & efficiency with time and cost. This development is estimated to propel the market growth opportunities over the forecast years. However, complex manufacturing and development procedures and a lack of specialized expertise may hinder the market growth during the estimated timeframe.
Competitive Landscape
Some Major Key Players In The Next-Generation Biomanufacturing Market:
- Applikon Biotechnology BV (Netherlands),
- bbi-biotech GmbH (Germany),
- Danaher Corporation (US),
- Eppendorf AG (Germany), Esco Group of Companies (US),
- GEA Group Aktiengesellschaft (Germany),
- Meissner Filtration Products, Inc. (US),
- Merck KGaA (Germany),
- PBS Biotech, Inc. (US),
- Pierre Guérin (France),
- Sartorius AG (Germany),
- Shanghai Bailun Biotechnology Co. Ltd. (China),
- Solaris Biotechnology Srl. (Italy),
- Thermo Fisher Scientific Inc. (US),
- ZETA GmbH (Austria),
Market Segmentation
The next-generation biomanufacturing market is segmented into medical applications, products, workflow, end-users, and regions. The medical applications segment comprises monoclonal antibodies, hormones, vaccines, recombinant proteins, and other applications. Due to their increasing medical applications, the monoclonal antibodies segment will dominate this market during the forecast years. Based on the products, the market is divided into continuous upstream biomanufacturing products, single-use upstream biomanufacturing products, and downstream biomanufacturing products. The market is classified into upstream and downstream biomanufacturing based on workflow. By end-users, the market is segmented into biopharmaceutical companies, CMOs (contract manufacturing organizations)/CDMOs (contract development and manufacturing organization), and research institutions. Biopharmaceutical companies are estimated to hold a significant market share in the coming years owing to the growing prevalence of chronic diseases and the high demand for protein/drug production. Region-wise, the market is studied across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
North America led the market due to the robust presence of large biopharmaceutical businesses, the improved infrastructure in biological research, and the rising usage of innovative technologies. The Asia-Pacific market is expected to witness the fastest growth during the forecast period due to the rapid adoption of advanced technologies, rising patient pool, and the high prevalence of chronic diseases. Apart from this, Europe holds the second position in this market regarding revenue share.
Recent Developments:
- In March 2023, Sartorius and LFB BIOMANUFACTURING, collaborate on the creation and production of cell lines. LFB BIOMANUFACTURING is a division of LFB, a well-known European business that supplies medical practitioners with plasma-derived pharmaceutical products. It specializes in therapeutic protein biomanufacturing.
Next-Generation Biomanufacturing Market Report Scope
| Report Attribute | Specifications |
| Market size value in 2024 | USD 24.9 Billion |
| Revenue forecast in 2034 | USD 80.0 Billion |
| Growth rate CAGR | CAGR of 12.6% from 2025 to 2034 |
| Quantitative units | Representation of revenue in US$ Billion and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments covered | By Medical Applications, Products, Workflow, End-User |
| Regional scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country scope | U.S.; Canada; U.K.; Germany; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia |
| Competitive Landscape | Applikon Biotechnology BV (Netherlands), bbi-biotech GmbH (Germany), Danaher Corporation (US), Eppendorf AG (Germany), Esco Group of Companies (US), GEA Group Aktiengesellschaft (Germany), Meissner Filtration Products, Inc. (US), Merck KGaA (Germany), PBS Biotech, Inc. (US), Pierre Guérin (France), Sartorius AG (Germany), Shanghai Bailun Biotechnology Co. Ltd. (China), Solaris Biotechnology Srl. (Italy), Thermo Fisher Scientific Inc. (US), ZETA GmbH (Austria), and other. |
| Customization scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and available payment methods | Explore pricing alternatives that are customized to your particular study requirements. |
Market Segmentation
Global Next-Generation Biomanufacturing Market, by Medical Applications,
- Monoclonal Antibodies
- Hormones
- Vaccines
- Recombinant Proteins
- Other Applications
Global Next-Generation Biomanufacturing Market, by Products,
- Continuous Upstream Biomanufacturing Products
- Single-Use Upstream Biomanufacturing Products
- Downstream Biomanufacturing Products
Global Next-Generation Biomanufacturing Market, by Workflow,
- Upstream Biomanufacturing
- Downstream Biomanufacturing
Global Next-Generation Biomanufacturing Market, by End-Users,
- Biopharmaceutical Companies
- CMOs (Contract manufacturing organizations)/CDMOs (Contract Development and Manufacturing Organization)
- Research Institutions
Global Next-Generation Biomanufacturing Market, by Region,
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
North America Next-Generation Biomanufacturing Market, by Country,
- U.S.
- Canada
Europe Next-Generation Biomanufacturing Market, by Country,
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific Next-Generation Biomanufacturing Market, by Country,
- India
- China
- Japan
- South Korea
- Australia & New Zealand
Latin America Next-Generation Biomanufacturing Market, by Country,
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa Next-Generation Biomanufacturing Market, by Country,
- South Africa
- Rest of Middle East & Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Next-Generation Biomanufacturing Market Size is valued at 24.9 Billion in 2024 and is predicted to reach 80.0 Billion by the year 2034
The Next-Generation Biomanufacturing Market is expected to grow at a 12.6% CAGR during the forecast period for 2025-2034.
Applikon Biotechnology BV (Netherlands), bbi-biotech GmbH (Germany), Danaher Corporation (US), Eppendorf AG (Germany), Esco Group of Companies (US), O
Next-Generation Biomanufacturing Market is segmented into medical applications, products, workflow, end-users, and regions.
North American region is leading the Next-Generation Biomanufacturing Market.